Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe by Gilbert, RE et al.




2, Eleonor G. Lago
3, Lilian M. G. Bahia-Oliveira




6, Miles R. Stanford
7, Eskild Petersen
8, for The European Multicentre
Study on Congenital Toxoplasmosis (EMSCOT)
1Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, London, United Kingdom, 2Albert Einstein College of Medicine, Department of
Epidemiology and Population Health, Bronx, New York, United States of America, 3Congenital Infections, Department of Pediatrics, Pontificia Universidade Cato ´lica do Rio
Grande do Sul, Porto Alegre, Brazil, 4Laboratorio de Biologia do Reconhecer, Centro de Biociencias e Biotecnologicas, Universidade Estadual do Norte Fluminense,
Campos dos Goytacazes, Goytacazes, Brazil, 5Laboratoire de Parasitologies Exotique, Ho ˆpital de la Croix Rousse, Lyon, France, 6Perinatal Infection Unit, Dept of
Pediatrics, University of Naples Federico II, Naples, Italy, 7Department of Academic Ophthalmology, King’s College London, London, United Kingdom, 8Department of
Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
Abstract
Background: Toxoplasmic retinochoroiditis appears to be more severe in Brazil, where it is a leading cause of blindness,
than in Europe, but direct comparisons are lacking. Evidence is accumulating that more virulent genotypes of Toxoplasma
gondii predominate in South America.
Methods: We compared prospective cohorts of children with congenital toxoplasmosis identified by universal neonatal
screening in Brazil and neonatal or prenatal screening in Europe between 1992 and 2003, using the same protocol in both
continents.
Results: Three hundred and eleven (311) children had congenital toxoplasmosis: 30 in Brazil and 281 in Europe, where 71
were identified by neonatal screening. Median follow up was 4.1 years in Europe and 3.7 years in Brazil. Relatively more
children had retinochoroiditis during the first year in Brazil than in Europe (15/30; 50% versus 29/281; 10%) and the risk of
lesions by 4 years of age was much higher: the hazard ratio for Brazil versus Europe was 5.36 (95%CI: 3.17, 9.08). Children in
Brazil had larger lesions, which were more likely to be multiple and to affect the posterior pole (p,0.0001). In Brazil, visual
impairment (,6/12 Snellen) was predicted for most affected eyes (87%, 27/31), but not in Europe (29%; 20/69, p,0.0001).
The size of newly detected lesions decreased with age (p=0.0007).
Conclusions: T. gondii causes more severe ocular disease in congenitally infected children in Brazil compared with Europe.
The marked differences in the frequency, size and multiplicity of retinochoroidal lesions may be due to infection with more
virulent genotypes of the parasite that predominate in Brazil but are rarely found in Europe.
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Introduction
Toxoplasmic retinochoroiditis appears to be more common in
Brazil than in Europe or North America and more severe. It is a
leading cause of blindness in Brazil[1] but not in Europe or North
America.[2,3] These differences are not adequately explained by high
rates of postnatal or congenital infection in Brazil, as similar rates of
i n f e c t i o nh a v eb e e no b s e r v e di nF r a n c ea n dE a s t e r nE u r o p e . [ 4 – 8 ]
Once infected, population-based studies of adolescents and adults,
most of whom have postnatally acquired infection, report the risk of
retinochoroiditis to vary from 2% in North Eastern Brazil to 25% in
Southern Brazil.[4,9–11] No comparable studies have been done in
Europe or North America but case series report risks of 0.3% to 1%
i na d u l t si nt h ey e a ro rt w oa f t e ra c quisition of infection.[12–14] The
fact that retinochoroiditis results in more and larger lesions in South
America than in Europe or North America is well accepted by
clinicians but differences could reflect delayed presentation due to
poor access to health care, referral bias, acquisition of infection from
oocysts rather than tissue cysts, or exposure to a higher parasite load
or to infection earlier in childhood in Brazil.[15] No published studies
have directly compared ocular sequelae of toxoplasmic infection in
Brazil with Europe or North America.
Differences in the ocular sequelae of toxoplasmosis have been
attributed to recent findings that distinctly different populations of
www.plosntds.org 1 August 2008 | Volume 2 | Issue 8 | e277Toxoplasma gondii exist in South America compared with Europe and
North America.[16,17] Strains in Brazil appear to be more virulent,
and have been identified in several patients with severe ocular
disease.[18,19] In-vitro studies suggest that strain virulence affects
triggering of the immune response, tissue penetration and the ability
to encyst. As treatment is effective only during the tachyzoite phase,
prior to encystment, this raises the possibility that the response to
anti-toxoplasma treatment may differ between strains.[20,21]
Possible clinical and policy implications of these findings could be
the development of targeted treatment and preventive strategies
depending on the prevailing parasite genotype.
Our aim was to inform clinical practice and policy, by quantifying
differences in ocular sequelae after toxoplasmic infection in Brazil
compared with Europe. We directly compared cohorts of children
with congenital toxoplasmosis identified by neonatal or prenatal
screening. This approach minimized differences in the route and
timing of infection as all fetuses were infected by transplacental
transmission of tachyzoites. Health care access was also similar as
screening was applied to all births, and we prospectively followed up
children using the same protocol in both continents.
Methods
Study population
We prospectively recruited and followed up a cohort of live-born
children with congenital toxoplasmosis identified between 1996 and
2003 by neonatal or delivery screening in 2 Brazilian centers, by
neonatal screening in 3 European centers (Sweden, Denmark, and
Poland), and by prenatal screening in 10 European centers (7 in
France, 2 in Italy, 1 in Austria). We also included children identified
in a prospective national Danish neonatal screening study between
1992 and 1996.[22] Details of screening methods and treatment in
the European centers have been reported elsewhere.[22–25] In all
centers, we excluded any mother or infant who was not first
identified by universal screening and who could have been referred
for testing because of symptomatology. The diagnosis of congenital
toxoplasmosis was based on persistence of specific IgG antibodies
after 11.5 months of age.[23,24]
In Brazil, neonatal screening was based on testing of the
neonatal Guthrie card blood spot using an IgM immunoassay
(VIDAS, Biomerieux) in Campos Dos Goytacazes, and a
commercial capture IgM fluorometric enzyme immunoassay
(Labsystems) in Porto Alegre. For screening of mothers at delivery,
an IgM immunoassay (VIDAS, BioMe ´rieux) was used.[26,27] In
Campos Dos Goytacazes, neonatal screening was offered to
approximately 25% of the total births (about 9,000 births per year)
who delivered on two days each week at public sector hospitals
within the area. Study infants were recruited between 1999 and
2001. In Porto Alegre, all patients were enrolled who had
congenital toxoplasmosis identified between 1998 and 2003 by
routine neonatal (n=17) or delivery (n=5) screening and who
started follow-up in the Congenital Infections Clinic of Sao Lucas
Hospital before 2 months of life (3 patients followed up elsewhere
were excluded). Twelve of these 22 children were followed up in
the public sector and 10 in the private sector. Postnatal treatment
was prescribed for 12 months. Pyrimethamine (1 mg/kg/day) and
sulphadiazine (100 mg/kg/day) given for the first six months were
changed for the subsequent six months to alternating spiramycin
and pyrimethamine-sulphonamide in Campos Dos Goytacazes
and to a lower dose of pyrimethamine (1 mg/kg/3 times per week)
with sulphonamide (100 mg/kg/day) in Porto Alegre.
Ophthalmic assessments
We used a standard questionnaire to record findings at routine
ophthalmoscopic examinations before 4 months, at 12 months of
age, and annually thereafter for all children in the cohort.
Clinicians were asked to dilate the pupil and use indirect
ophthalmoscopy. They used a standard proforma to record
whether the retina was adequately visualized, describe the site of
lesions using a diagram and text, and estimate lesion size in
multiples of the optic disc diameter. We defined a recurrence as a
new lesion that was detected for the first time more than one week
after a previous adequate visualization of the retina. Analyses of
lesion size were based on the size of the largest lesion at each new
occurrence. Multiple lesions were based on the total number of
separate lesions detectable at the last examination. We assumed
that 2 included children (in Brazil and Europe) had retinocho-
roiditis although microphthalmia and severe vitreal opacities
prevented adequate examination. One of us (MRS) categorized
each eye according to whether visual impairment (,6/12 Snellen)
was likely or not based on the last retinal diagram. MRS was
blinded to visual acuity results.
Analysis
The incidence of first or recurrent lesions was calculated from
the number of new detections and the child years of follow up
using a generalized linear model with a Poisson distribution with a
log link function and the 95% confidence interval was derived.
Kaplan Meier curves were derived to describe the time to first
detection of the first lesion after birth. If a child had no lesions,
censoring occurred at the date of the last ophthalmic examination.
The probability of lesions by 4 years of age was derived from the
product-limit estimates of the survivor function. We used Cox
proportional hazards regression to compare differences in the age
at detection of the first retinochoroidal lesion in Brazil with
European screening centers. As no significant difference was
detected between the time to first lesion in European prenatal and
neonatal screening centers we compared the size of lesions, risk of
recurrence and multiplicity of lesions in the combined European
cohort with children in Brazil. The mean size of the largest lesion
at each new lesion occurrence was compared using a hierarchical
linear model to take into account multiple occurrences in the same
child. Results of autoregressive and compound symmetric models
were examined to identify the best model (i.e. that with the lowest
AIC statistic).[28] Using the dataset combining all children, we
Author Summary
Toxoplasma gondii is found throughout the world and is
the most common parasitic infection in humans. Infection
can cause inflammatory lesions at the back of the eye,
which sometimes affect vision. These complications
appear to be more common and more severe when
people acquire infection in Brazil than in Europe or North
America, but there have been no direct comparisons of
patients identified and followed up in the same way. In this
report, we compare children with congenital toxoplasmo-
sis diagnosed at birth by universal screening in Europe and
Brazil and followed up until the age of 4. We found that
Brazilian children had a 5 times higher risk than European
children of developing eye lesions and their lesions were
larger, more numerous and more likely to affect the part of
the area of the retina responsible for central vision. Two-
thirds of Brazilian children infected with congenital
toxoplasmosis had eye lesions by 4 years of age compared
with 1 in 6 in Europe. These stark differences are likely to
be due to the predominance of more virulent genotypes
of the parasite in Brazil, which are rarely found in Europe.
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recurrent lesions using methods for multiple failure time data. We
used the PWP total time model with common effects[29,30] which
assumes that a subject cannot be at risk for a k
th eye lesion unless
the (k-1)
th lesion has occurred. We chose this model for two
reasons. First, the possibility that the infection process or immune
response that affects time to initial eye lesion may also impact on
times to subsequent lesions, and each period evaluated might
present different baseline risks. Second, results were consistent
with other approaches, but the PWP model yielded the most
conservative hazards ratio.
Ethics review
Research ethics approval was required for five cohorts where
neonatal screening and follow up of positive results was not
established routine practice: the two Brazilian centers, patients
screened in Denmark between 1992 and 1995, and in Sweden and
Poland. In Brazil, screening and follow up was approved by the
Ethical ReviewBoard ofthePontificia Universidade Cato ´licadoRio
Grande do Sul, Porto Alegre, Brazil, the Ethical Review Board of
Fundac ¸a ˜o Oswaldo Cruz (FIOCRUZ) in Rio de Janeiro, Brazil.
Mothers were given information during pregnancy about the
screening study and verbal consent was obtained for testing at the
time of sampling. Refusal to participate in screen testing was
recordedbyremovingthecardusedfortoxoplasma testing. Separate
writtenconsentwasobtainedfromparentsofscreenpositivechildren
to participate in the follow up study. None refused. In the Danish
study from 1992–1995, in Sweden and in Poland, mothers were
given information during pregnancy or at delivery. At the time of
blood sampling, verbal consent was obtained to screen testing and to
follow up if found to be positive. Refusal to participate was recorded
in writing on the filter paper card. This approach of using oral
consent to testing and follow up was approved by the Scientific
EthicsCommittee ofCopenhagen(V100.1689/90 andL02033),the
Ethical Committee at Huddinge Hospital, Stockholm (No. 96-089),
and the Scientific Ethical Committee of the Karol Marcinkowski
University of Medical Sciences in Poznan ´.
In all other cohorts (in France, Italy, Austria and Denmark from
1996 onwards) screening and follow up of positive test results was
part of universal, routinely provided care. Research ethics
approval was not required at the time of the study in any of
these centers because all three of the following criteria were met:
the study did not involve any modification of routine practice and
had no impact on patient care; data collected for the study were
confined to information held in routine records of screen test
results and follow up examinations; and data were anonymized
prior to collation for the study. We specifically requested that the
Research Ethics Committee of Great Ormond Street Hospital
scrutinize the study and provide written confirmation that research
ethics review was not required in the UK before the start of
prospective data collection in 1996.
Results
Study population
The study compared 30 infected children identified by neonatal
screening in Brazil with 71 children identified by neonatal screening
(29 in Poland and 42 in Scandinavia) and 210 by prenatal screening
in Europe (171 in France, 15 in Italy and 24 in Austria). All had at
least one ophthalmoscopic exam and reports of inadequate
visualization of the retina were rare. No screen positive children
were excluded in Brazil but in Europe, 5 children were excluded due
to possible referral bias and a further 3 because they had no
ophthalmoscopic exam. The shortest interval between a negative
examination and a new lesion occurrence was 22 days. None of the
mothers of children in the neonatal centers were treated during
pregnancy, whereas 178/210 (85%) in the prenatal centers were
treated. All except3 children (allinEurope) were treated postnatally,
mostly for 1 year (further details reported elsewhere).[22,23,27] The
median age at the start of postnatal treatment was 3 days (IQR: 0,
15) in prenatal centers, 27 days (IQR: 23, 34) in European neonatal
centers, and 47 days (IQR 25, 82) in Brazilian centers.
Occurrence of retinochoroiditis
The survival analyses in Figure 1 show that more children
developed retinochoroiditis sooner in Brazil than in Europe. The
hazard ratio shows a markedly increased risk of early retinochor-
oidal lesion in Brazil than in Europe (Table 1; p,0.0001). There
was no evidence that the time to first lesion differed between
European neonatal and prenatal screening centers (p=0.9601;
Table 1 and Figure 1). The hazard ratio for time to first
retinochoroidal lesion in neonatal centers in Brazil compared with
neonatal centers in Europe was 2.37 (95%CI: 1.62, 3.47).
Recurrence
Retinochoroidal lesion recurred at an earlier age in Brazil than
in Europe (p=0.0406; Table 1). By 4 years of age, the probability
of a second lesion among children with a first lesion was 43% in
Brazil compared with 29% in Europe (Table 1). The risk of
multiple recurrences was also greater in Brazil (hazard ratio for the
time from birth to multiple lesions: 3.44; 95%CI: 2.23, 5.32).
There was no significant difference in the age at recurrence
between European prenatal and neonatal screening centers
(p=0.1740) (Table 1).
Site of lesions
Children in Brazil were more likely than those in Europe to
have retinochoroidal lesions that affected the posterior pole and to
have visual impairment predicted by the ophthalmologist assessing
the retinal diagrams (p,0.001; Table 1). Relatively more children
in Brazil than Europe had multiple lesions (p,0.0001).
Size of lesions
The size of the largest lesion was recorded for 62% (74/119) of
first or recurrent lesions. Figures 2 A to C depict the size of the
largest lesion for each lesion occurrence according to age at
detection. The overall mean size was greater in Brazil than in
Europe (p,0.0001, Table 1). In both continents, lesion size
decreased with the age at detection (p=0.0007).
Figure 1. Survival analyses showing proportion of children
without retinochoroiditis according to age in years when first
eye lesion was detected in Brazil (solid line), and European
neonatal (long dash) and prenatal centers (short dash).
doi:10.1371/journal.pntd.0000277.g001
Ocular Toxoplasmosis in Brazil versus Europe
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Children with congenital toxoplasmosis in Brazil developed
retinochoroiditis earlier than children in Europe, had multiple
lesions more frequently, and had larger lesions that were more
likely to affect the posterior pole and hence to threaten vision.
Lesions appeared to diminish in size with age at detection.
This is the first study to compare toxoplasmic retinochoroiditis
in concurrent cohorts from Brazil and Europe. Strengths of the
study include prospective enrollment and follow up of children in
the same way in both continents. A potential source of bias is the
fact that Brazilian ophthalmologists have more experience with
toxoplasmic retinochoroiditis than their European counterparts
and used indirect ophthalmoscopy for virtually all examinations
Table 1. Occurrence of retinochoroiditis in children with congenital toxoplasmosis in Brazil compared with Europe
Europe Europe Europe Brazil
Neonatal Prenatal TOTAL Neonatal
N=71 N=210 N=281 N=30
*
Period of recruitment 1992–2000 1996–1999 1999–2002
Examinations
Median age (years) at last ophthalmoscopy (range) 4.2 (0.08, 11.46) 4.0 (0.01, 7.50) 4.08 (0.01, 11.46) 3.65 (0.38, 8.47)
Median ophthalmology exams (range) 6 (1, 18) 4 (1, 13) 4 (1, 18) 4 (1, 9)
Indirect ophthalmoscopy/all examinations (%) 251/351 (71) 468/984 (48) 719/1335 (54) 127/135 (94)
Frequency of retinochoroidal lesions
Incidence lesion(s) detection/child year at risk (95%CI) 0.083 (0.056, 0.118) 0.072 (0.055,0.094) 0.076 (0.061, 0.093) 0.334 (0.238, 0.454)
Any retinochoroiditis (%) 16 (23) 34 (16) 50/281 (18) 20 (67)
Any retinochoroiditis in infancy (%) 10 (14) 25 (12) 35/281 (12) 15 (50)
Probability of lesions by 4 years (95%CI) 0.160 (0.073, 0.228) 0.167 (0 112, 0.221) 0.164 (0.118, 0.210) 0.659 (0.465, 0.853)
Hazard ratio for time to first lesion (95%CI) 1.02 (0.54, 1.92) { 5.36 (3.17, 9.08) {
Lesion recurrence (in children with retinochoroiditis) 1 15 34 49 19
Median number of recurrences/affected child (range; IQR) 1 (1 ,3; 1) 1 (1, 3; 1) 1 (1 ,3; 1) 2 (1, 4; 1)
Incidence rate: one or more recurrences/child year at risk 0.208 (0.112, 0.349) 0.206 (0.128, 0.309) 0.207(0.143, 0.287) 0.298 (0.178, 0.463)
Lesion recurrence (%) 7 (44) 14 (41) 21 (42) 12 (60)
Probability of recurrence by 4 years of age (95%CI) 0.196 (0.000, 0.396) 0.343 (0.168, 0.518) 0.290 (0.156, 0.424) 0.428 (0.201, 0.656)
Hazard ratio for time to second lesion from birth (95%CI) 0.47 (0.16, 1.40) { 1 1 2.20 (1.03, 4.67) {
Hazard ratio for time to second lesion from first (95%CI) 0.77 (0.29, 2.05) { 1 1 1.82 (0.88, 3.77) {
Multiple lesions (in children with retinochoroiditis)
Total number of lesions 35 70 105 66
Median number lesions/affected child (range; IQR) 2 (1,5;3) 2 (1,5;2) 2 (1,5;2) 3 (1,8;3)
Eyes affected by lesions 23 (16) 46 (11) 69 (12) 31 (52)
Eyes with multiple lesions (%) 8 (35) 20 (43) 28 (41) 19 (61)
Site of lesion
Any bilateral lesion (% affected children) 8 (53) 12 (35) 20 (41) 12 (63)
Bilateral posterior pole lesion (% affected children) 1 (7) 6 (18) 7 (14) 8 (42)
Posterior pole lesion (% affected eyes) 9 (39) 30 (65) 39 (57) 25 (81)
Mean size of lesion " (range)
All ages 1.54 (45) 1.62 (29)
,2 years (number) 1.76 (30) 2.32 (17)
2 to 4 years (number) 1.1 (5) 0.71 (6)
.4 years (number) 1.1 (10) 0.52 (6)
Predicted visual impairment||
Anticipated visual impairment in best eye 1 (7) 4 (12) 5 (10) 11 (37)
Anticipated visual impairment(% affected eyes) 7 (30) 13 (28) 20 (28) 27 (87)
*Three children from Brazil were included in a previous study by Neto et al.[27]
{Compared with Europe prenatal
{Compared with Europe total
1Excludes two children (1 Europe prenatal and 1 Brazil) with presumed retinochoroiditis, microphthalmia and vitreal opacities in whom recurrence could not be assessed.
||Based on ophthalmologist assessment of retinal diagrams. Criteria for impairment is acuity ,6/12. Five eyes without diagrams assumed to be unimpaired based on
reported site of lesions.
"Mean size of the largest lesion at each new lesion occurrence measured in disc diameters. Europe datasets combined because of small numbers
IQR=interquartile range
doi:10.1371/journal.pntd.0000277.t001
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(73% of European children had at least one indirect examination).
Such detection bias is unlikely to explain the very large differences
between Brazil and Europe, which persisted for posterior pole
lesions, which all ophthalmologists should be able to detect
regardless of ophthalmoscopy method.
There are three possible confounding factors that could have
contributed to the differences in the risk of retinochoroiditis
between Brazil and Europe. Firstly, two-thirds of children in the
European cohort received prenatal treatment. We have reported
elsewhere that prenatal treatment did not statistically significantly
reduce the risk of retinochoroiditis, and similar findings have been
reported by others.[23,31–33] Moreover, the differences between
Brazil and Europe persisted when we compared neonatal screening
centers in Brazil and Europe. The fact that postnatal treatment was
started later in Brazil than in European neonatal screening centers
would not affect the higher prevalence of lesions at birth in Brazil.
Secondly, the mothers of children in Brazil would have serocon-
verted on average later in pregnancy than those identified by
prenatalscreeninginEuropebecauseIgMscreeningfavorsdetection
of children infected in the latter half of pregnancy.[34] Given the
weak association between early gestational age at maternal
seroconversion and the risk of retinochoroiditis, our results would
be biased in favor of underestimating differences in the risk of
retinochoroiditis in Brazil compared with Europe.[23,31,32]
Thirdly, termination of fetuses with ocular disease in the prenatal
centers could have reduced the risk of ocular disease in Europe. This
seems unlikely as the number of pregnancy terminations for
toxoplasmosis in European prenatal screening centers was very
low: 17 out of 1327 women had terminations for toxoplasmosis, of
which 9 were infected and very few (n=6) had evidence of clinical
manifestations at autopsy.[35]
Differences between cohorts in calendar time and ethnicity are
unlikely to account for the large differences observed between
Europe and Brazil. Previous analyses based on European data have
shown weak effects of calendar time, with a decreased risk of lesions
in later years. This source of bias would lead to an underestimate of
the difference between the two continents. Ethnic variation is
unlikely to explain the very large differences observed as epidemi-
ological studies have shown that the prevalence of toxoplasmic
infection and ocular disease in populations is associated with country
of birth and region of early childhood, rather than ethnicity.[36,37]
Differences between Brazil and Europe are unlikely to be due to
anomalies in the regions included in the cohort. Within Europe,
increasing latitude has been weakly associated with a diminished risk
of clinical manifestations, but the European cohort was representa-
tive of all latitudes across western Europe with children recruited
from southern, central and northern Europe. The Brazilian cohort
was representative of the mix of public and private provision of
health care in Brazil where 20% of the population have private
health care but our findings differed from a previous cohort study of
children with congenital toxoplasmosis in Brazil, which found that
the risk of clinical manifestations (intracranial and/or ocular lesions)
inthefirst year of life(17%;8/47)was verysimilartoEurope.[27,31]
This low rate of ocular disease in the study by Neto et al may reflect
inadequate follow up, a reduced risk in more affluent socioeconomic
groups, or regional variation in the incidence of exposure to
toxoplasmosis and risk of ocular disease in Brazil.[4,6,38] The study
by Neto et al was based on children from all regions of Brazil whose
families could afford private health care, whereas the present study
was based in two endemic areas and only one-third of the children
had privatehealthcare.However,wefound noevidence thatthe risk
of retinochoroiditis differed according to public (12/20) or private
sector patients (8/10). Incidence rates of congenital toxoplasmosis in
Porto Alegre are alsosimilar inthe private andpublicsectors(private
4.4/10,000 live births; 95%CI : 1.3–9.6, in 1998–2003; public 6.0/
10,000; 95%CI: 2.4–12.5, in 2002; personal communication EG
Lago, Porto Alegre).
We suggest that the increased frequency and severity of ocular
disease in Brazil compared with Europe is due to exposure to more
virulent strains of T.gondii in Brazil. Type 1 and atypical strains
appear to be associated with more severe ocular disease[18,19]
Figure 2. Size measured in disc diameters (y axis) and age
(years, x axis) of the first (black), second (blue) and third (red)
and fourth (green) newly detected retinochoroidal lesions in
(A) Brazil, and (B) European Neonatal Centers and (C)
European Prenatal Centers.
doi:10.1371/journal.pntd.0000277.g002
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North America.[16,17,38–41] The increased virulence of strains in
Brazil compared with Europe may reflect more frequent sexual
reproduction in the life-cycle of T.gondii in Brazil and human
exposure to recombinant strains due to more frequent acquisition
of infection via oocysts in Brazil.[42] Recent in-vitro studies
suggest that the more virulent strains have a higher rate of growth,
a remarkable ability to migrate across epithelial barriers to
penetrate host tissue,[43] and can down regulate interleukin 12
more efficiently than the type II strain, which could impair the
child’s protective immune response.[20,21,44]
The finding that the size of lesions diminished with time since
infection has not been reported previously. Cautious interpretation
is required as detection bias could explain this finding if small
lesions are more readily detected as ophthalmoscopy becomes
easier with age. Alternatively, lesions may be walled off more
effectively as the host immune response matures or the organism
load may diminish as bradyzoite cysts involute. Ophthalmologist
predictions for visual impairment should also be regarded with
caution. These were used as a surrogate measure as children in
Brazil did not have visual acuity measures. However, limited
accuracy in ophthalmologist prediction (85% specific and 59%
sensitive for visual impairment of ,6/18 Snellen),[45] is unlikely
to explain the very large differences in predicted visual impairment
observed between Brazil and Europe.
Further research is required to determine whether virulence
factors are associated with prolongation of the tachyzoite phase,
which could create a longer therapeutic window before tissue cyst
formation when anti-toxoplasmic treatment might be effective.
Prospective cohort studies in Europe have shown no evidence for a
protective effect of prenatal treatment on ocular disease and data
from the EMSCOT study found no effect of postnatal treatment,
although the power to detect an effect was limited.[31–33] Clearly
postnatal treatment was not highly effective in 13/20 children in
the Brazil cohort, who developed 17 new lesions while on
treatment for at least two weeks (as did 15/50 children with18
lesions in the European cohort). Randomized controlled trials are
needed most urgently in South America to determine the
effectiveness of postnatal treatment for congenital toxoplasmosis
and hence, whether neonatal screening is worthwhile. Extrapola-
tion of results on treatment effectiveness across continents may not
be justified in view of the possibility that pharmacodynamics might
differ according to parasite genotype.
Conclusions
In Brazil, congenital toxoplasmosis resulted in more frequent
and more severe ocular disease than in Europe. There is indirect
evidence that these differences may be related to the predomi-
nance of virulent genotypes of the T.gondii parasite in Brazil.
Randomized controlled trials are urgently needed in South
America to determine treatment efficacy and the clinical
effectiveness of neonatal screening.
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